Opthea Receives A$6.6 m R&D Tax Incentive
January 24, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 04, 2022 06:18 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD
January 03, 2022 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Granted Chinese Patent Covering OPT-302
October 26, 2021 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
October 19, 2021 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Opens Patient Recruitment in Europe for Pivotal Phase 3 ShORe and COAST Wet AMD Trials of OPT-302
October 04, 2021 07:00 ET
|
Opthea Limited
MELBOURNE, Australia, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Present at September Investor Conferences
September 02, 2021 07:00 ET
|
Opthea Limited
MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights
August 30, 2021 07:00 ET
|
Opthea Limited
Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD) OPT-302 Granted FDA Fast Track Designation for Wet AMD Received FDA Waiver for Pediatric...
Opthea To Present at the H.C. Wainwright Ophthalmology Virtual Conference
August 10, 2021 07:00 ET
|
Opthea Limited
MELBOURNE, Australia, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada
August 09, 2021 07:00 ET
|
Opthea Limited
MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...